Scott Drake
Chief Executive Officer
Executives
Spectranetics
Netherlands
Biography
Scott Drake has served as President and Chief Executive Officer of Spectranetics (NASDAQ: SPNC) since 2011. Under Drake’s leadership, revenue grew from $117.9 million in 2010 to $245.9 million in 2015. Drake’s engineering of the 2014 acquisition of AngioScore Inc. and the 2015 acquisition of the Stellarex™ drug-coated balloon platform broadened the company’s portfolio for delivering clinical solutions for complex cardiovascular conditions and paved the way for future growth. Prior to joining Spectranetics, Drake served as Senior Vice President, Operations, of DaVita, Inc. (NYSE: DVA), a leading U.S. provider of kidney care and dialysis. His operations generated more than $6 billion of revenue, or about 20% of DaVita’s total revenue. Previously, Drake spent 17 years in several leadership positions within numerous health care business units at Covidien. From 2006 to 2009, Drake was Global Business Unit President, Respiratory and Monitoring Solutions, a $1.5 billion business with 8,000 employees. Drake was named an EY 2014 Entrepreneur Of The Year™. He is Chairman of the Board of Just Right Surgical and serves on the board of directors for The Spectranetics Corporation, AtriCure (NASDAQ: ATRC), and the Medical Device Manufacturers Association (MDMA). He earned a BS in Business Administration from Miami University of Ohio.
Research Interest
cardiovascular
